RU2013123793A - Антитела, связывающиеся с notum пектинацетилэстеразой - Google Patents

Антитела, связывающиеся с notum пектинацетилэстеразой Download PDF

Info

Publication number
RU2013123793A
RU2013123793A RU2013123793/10A RU2013123793A RU2013123793A RU 2013123793 A RU2013123793 A RU 2013123793A RU 2013123793/10 A RU2013123793/10 A RU 2013123793/10A RU 2013123793 A RU2013123793 A RU 2013123793A RU 2013123793 A RU2013123793 A RU 2013123793A
Authority
RU
Russia
Prior art keywords
seq
amino acid
acid sequence
variable region
sequence
Prior art date
Application number
RU2013123793/10A
Other languages
English (en)
Russian (ru)
Inventor
Роберт Джозеф Дж. БРОМЭДЖ
Сяо Фэн
Сёкджу ХОНГ
Грегори ЛЭНДС
Джефф ЛЬЮ
Дэвид Джордж ПОТТЕР
Дэвид Рид ПАУВЕЛЛ
Original Assignee
Лексикон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Лексикон Фармасьютикалз, Инк. filed Critical Лексикон Фармасьютикалз, Инк.
Publication of RU2013123793A publication Critical patent/RU2013123793A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
RU2013123793/10A 2010-11-24 2011-11-22 Антитела, связывающиеся с notum пектинацетилэстеразой RU2013123793A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41692710P 2010-11-24 2010-11-24
US61/416,927 2010-11-24
PCT/US2011/061785 WO2012071381A1 (en) 2010-11-24 2011-11-22 Antibodies to notum pectinacetylesterase

Publications (1)

Publication Number Publication Date
RU2013123793A true RU2013123793A (ru) 2014-12-27

Family

ID=46146184

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013123793/10A RU2013123793A (ru) 2010-11-24 2011-11-22 Антитела, связывающиеся с notum пектинацетилэстеразой

Country Status (21)

Country Link
US (3) US20130302346A1 (enExample)
EP (1) EP2643019B1 (enExample)
JP (1) JP6033229B2 (enExample)
KR (2) KR20180069083A (enExample)
CN (1) CN103298490B (enExample)
AU (1) AU2011332007C1 (enExample)
BR (1) BR112013012858B1 (enExample)
CA (1) CA2817415C (enExample)
CO (1) CO6721048A2 (enExample)
DK (1) DK2643019T3 (enExample)
ES (1) ES2718849T3 (enExample)
HU (1) HUE043576T2 (enExample)
IL (1) IL225876A0 (enExample)
MX (2) MX385858B (enExample)
NZ (1) NZ609501A (enExample)
PL (1) PL2643019T3 (enExample)
PT (1) PT2643019T (enExample)
RU (1) RU2013123793A (enExample)
SG (1) SG189982A1 (enExample)
WO (1) WO2012071381A1 (enExample)
ZA (1) ZA201302983B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201506782XA (en) * 2010-08-27 2015-10-29 Stem Centrx Inc Notum protein modulators and methods of use
MX385858B (es) 2010-11-24 2025-03-18 Lexicon Pharmaceuticals Inc Anticuerpos que se unen a notum pectinacetilesterasa.
EP3252076B1 (en) 2011-01-14 2019-09-04 The Regents Of The University Of California Diagnostic use of antibodies against ror-1 protein
US8802365B2 (en) * 2011-03-22 2014-08-12 Whitehead Institute For Biomedical Research Methods for identifying candidate modulators of NOTUM activity
AU2013310924B2 (en) * 2012-08-31 2017-08-03 Argenx Bvba Method for producing antibody molecules having inter-species, intra-target cross-reactivity
IL254039B2 (en) 2015-02-19 2023-12-01 Compugen Ltd Anti-pvrig antibodies and methods of use
KR102585976B1 (ko) 2016-08-17 2023-10-05 컴퓨젠 엘티디. 항-tigit 항체, 항-pvrig 항체 및 이들의 조합
WO2020150282A1 (en) * 2019-01-18 2020-07-23 Askgene Pharma Inc. Pd-l1 specific monoclonal antibodies for disease treatment and diagnosis
CN110317271B (zh) * 2019-07-02 2021-04-30 武汉云克隆科技股份有限公司 一种pinp重组抗体的重/轻链可变区及编码基因和重组抗体
US20240109973A1 (en) * 2020-12-16 2024-04-04 Memorial Sloan Kettering Cancer Center Cd40 binding molecules and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
AU1674292A (en) 1991-03-15 1992-10-21 Synergen, Inc. Pegylation of polypeptides
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW313568B (enExample) 1994-12-20 1997-08-21 Hoffmann La Roche
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6080576A (en) 1998-03-27 2000-06-27 Lexicon Genetics Incorporated Vectors for gene trapping and gene activation
GB0201808D0 (en) * 2002-01-25 2002-03-13 European Molecular Biology Lab Embl Protein
US20040063924A1 (en) * 2002-01-28 2004-04-01 Y Tom Tang Secreted proteins
ATE528397T1 (de) * 2003-08-08 2011-10-15 Perseus Proteomics Inc Bei krebs überexprimiertes gen
SG10201506782XA (en) * 2010-08-27 2015-10-29 Stem Centrx Inc Notum protein modulators and methods of use
MX385858B (es) 2010-11-24 2025-03-18 Lexicon Pharmaceuticals Inc Anticuerpos que se unen a notum pectinacetilesterasa.

Also Published As

Publication number Publication date
PL2643019T3 (pl) 2019-07-31
CA2817415A1 (en) 2012-05-31
KR20140026334A (ko) 2014-03-05
BR112013012858B1 (pt) 2021-12-07
CN103298490B (zh) 2017-04-26
US20130302346A1 (en) 2013-11-14
ES2718849T3 (es) 2019-07-04
CA2817415C (en) 2020-05-12
DK2643019T3 (en) 2019-04-15
JP6033229B2 (ja) 2016-11-30
ZA201302983B (en) 2017-06-28
EP2643019B1 (en) 2019-01-02
CN103298490A (zh) 2013-09-11
MX2013005906A (es) 2013-06-28
US11059907B2 (en) 2021-07-13
AU2011332007C1 (en) 2017-03-02
JP2014501513A (ja) 2014-01-23
BR112013012858A2 (pt) 2018-09-04
HUE043576T2 (hu) 2019-08-28
WO2012071381A1 (en) 2012-05-31
KR20180069083A (ko) 2018-06-22
SG189982A1 (en) 2013-06-28
MX357166B (es) 2018-06-28
US20160152731A1 (en) 2016-06-02
EP2643019A4 (en) 2014-12-31
IL225876A0 (en) 2013-06-27
MX385858B (es) 2025-03-18
PT2643019T (pt) 2019-04-23
US20190241677A1 (en) 2019-08-08
CO6721048A2 (es) 2013-07-31
EP2643019A1 (en) 2013-10-02
AU2011332007B2 (en) 2016-11-10
NZ609501A (en) 2014-12-24
AU2011332007A1 (en) 2013-05-09

Similar Documents

Publication Publication Date Title
JP5758933B2 (ja) 抗スクレロスチン抗体
EP2417158B9 (en) Dkk-1 antibodies
ES2340205T3 (es) Anticuerpos anti-egfr.
JP7576022B2 (ja) 抗ＩＬ－１β抗体およびその医薬組成物およびそれらの使用
KR20060133049A (ko) 항-마이오스타틴 항체
JP2014501513A5 (enExample)
JP2021514960A (ja) 抗ＴｒｋＡ抗体
CN109069637A (zh) 治疗骨疾病、病症和/或损伤的方法以及用于所述方法的试剂
KR20240082380A (ko) 골형성 부전증의 치료에 항-스클레로스틴 항체를 사용하는 방법
JP2020525421A (ja) 尿失禁を予防及び治療するための方法
CN122011204A (zh) 双功能融合蛋白及其应用
EP1951759B1 (en) Anti-egfr antibodies
TW202430555A (zh) 重組抗體、包含該重組抗體的藥學組合物及其於治療癌症之用途
HK1162183A (en) Dkk-1 antibodies
HK1162183B (en) Dkk-1 antibodies

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20160617